AIMS/HYPOTHESIS: Pancreatic beta cells undergo dynamic remodelling during the perinatal period, with enhanced neogenesis, proliferation and apoptosis observed. The molecular mechanisms responsible for these processes have yet to be elucidated. Survivin is an inhibitor of apoptosis, first described as being exclusively expressed in tumour and embryonic tissues with regulatory functions in mitosis and apoptosis. The aim of the present study was to define the essential physiological role of survivin in the pancreas. METHODS: The expression profile of survivin was assessed in the mouse pancreas, and we generated a Pdx1 promoter-driven Survivin (also known as Birc5) knockout mouse using the Cre-loxP recombination system to determine the essential physiological function of survivin in the pancreas. RESULTS: Survivin is transiently expressed in mouse pancreatic islets during the embryonic and neonatal periods. Targeted deletion of Survivin in the pancreas resulted in a significant decline in beta cell mass throughout the perinatal period, leading to glucose intolerance in the adult. Survivin-deficient islets showed decreased cell proliferation as a result of a delay in cell cycle progression with perturbations in cell cycle proteins. Survivin did not, however, play an essential role in beta cell apoptosis either during the physiological remodelling period or in response to streptozotocin. Islet development, islet architecture, microvasculature and apoptosis were not affected by the absence of survivin in the pancreas. CONCLUSIONS/ INTERPRETATION: Survivin expression in the pancreatic islets during the perinatal remodelling period is essential for the establishment of beta cell mass through cell cycle regulation.
AIMS/HYPOTHESIS: Pancreatic beta cells undergo dynamic remodelling during the perinatal period, with enhanced neogenesis, proliferation and apoptosis observed. The molecular mechanisms responsible for these processes have yet to be elucidated. Survivin is an inhibitor of apoptosis, first described as being exclusively expressed in tumour and embryonic tissues with regulatory functions in mitosis and apoptosis. The aim of the present study was to define the essential physiological role of survivin in the pancreas. METHODS: The expression profile of survivin was assessed in the mouse pancreas, and we generated a Pdx1 promoter-driven Survivin (also known as Birc5) knockout mouse using the Cre-loxP recombination system to determine the essential physiological function of survivin in the pancreas. RESULTS:Survivin is transiently expressed in mousepancreatic islets during the embryonic and neonatal periods. Targeted deletion of Survivin in the pancreas resulted in a significant decline in beta cell mass throughout the perinatal period, leading to glucose intolerance in the adult. Survivin-deficient islets showed decreased cell proliferation as a result of a delay in cell cycle progression with perturbations in cell cycle proteins. Survivin did not, however, play an essential role in beta cell apoptosis either during the physiological remodelling period or in response to streptozotocin. Islet development, islet architecture, microvasculature and apoptosis were not affected by the absence of survivin in the pancreas. CONCLUSIONS/ INTERPRETATION:Survivin expression in the pancreatic islets during the perinatal remodelling period is essential for the establishment of beta cell mass through cell cycle regulation.
Authors: Jake A Kushner; Maria A Ciemerych; Ewa Sicinska; Lynn M Wartschow; Monica Teta; Simon Y Long; Piotr Sicinski; Morris F White Journal: Mol Cell Biol Date: 2005-05 Impact factor: 4.272
Authors: Janakiraman Krishnamurthy; Matthew R Ramsey; Keith L Ligon; Chad Torrice; Angela Koh; Susan Bonner-Weir; Norman E Sharpless Journal: Nature Date: 2006-09-06 Impact factor: 49.962
Authors: Ralph A DeFronzo; Robert E Ratner; Jenny Han; Dennis D Kim; Mark S Fineman; Alain D Baron Journal: Diabetes Care Date: 2005-05 Impact factor: 19.112
Authors: Femke Zwerts; Florea Lupu; Astrid De Vriese; Saskia Pollefeyt; Lieve Moons; Rachel A Altura; Yuying Jiang; Patrick H Maxwell; Peter Hill; Hideyasu Oh; Claus Rieker; Désiré Collen; Simon J Conway; Edward M Conway Journal: Blood Date: 2007-02-13 Impact factor: 22.113
Authors: Shane P Simonett; Sunyoung Shin; Jacob A Herring; Rhonda Bacher; Linsin A Smith; Chenyang Dong; Mary E Rabaglia; Donnie S Stapleton; Kathryn L Schueler; Jeea Choi; Matthew N Bernstein; Daniel R Turkewitz; Carlos Perez-Cervantes; Jason Spaeth; Roland Stein; Jeffery S Tessem; Christina Kendziorski; Sündüz Keleş; Ivan P Moskowitz; Mark P Keller; Alan D Attie Journal: J Clin Invest Date: 2021-11-01 Impact factor: 14.808
Authors: Haijuan Wang; Katarina Gambosova; Zachary A Cooper; Michael P Holloway; Andrea Kassai; Denisse Izquierdo; Kelly Cleveland; Charlotte M Boney; Rachel A Altura Journal: BMC Mol Biol Date: 2010-08-31 Impact factor: 2.946